Clinical trials: Treatment Resistant Psychosis
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or…
- Trial name
- NCT00231335
- Testing
- escitalopram
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Schizophrenia
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
In this study, the investigators will investigate the impact and the related mechanism of metformin treatment on cognitive impairment of schizophrenia with a high risk of metabolic syndrome.
- Trial name
- NCT03271866
- Testing
- metformin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Central South University
Treatment-resistant Schizophrenia
Deep Brain Stimulation in Treatment Resistant Schizophrenia
The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia.
- Trial name
- NCT02361554
- Testing
- Medtronic Percept with SensSight Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Serious Mental Illness
Cross-Sectional Iloperidone IVGTT
This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a…
- Conditions
- Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance
- Trial name
- NCT01686815
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia
The GiSAS study is a multi-centre randomized clinical trial that will involve about 80 italian community psychiatric services in Italy and will recruit 800 patients affected by schizophrenia.
- Trial name
- GiSAS (NCT01052389)
- Testing
- Aripiprazole, Olanzapine, Haloperidol
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Metabolic Syndrome
The Impact of Dietary Habits and Nutrition Intervention on Metabolic Syndrome in Individuals With Schizophrenia
Metabolic syndrome is a term used to describe a complex clinical condition that includes abdominal obesity, increased level of serum triglycerides, elevated blood pressure, decreased level of high-density lipoprotein cholesterol…
- Trial name
- NCT04025073
- Testing
- Dietary Approaches to Stop Hypertension, Nutrition education program
- Where
- Croatia
- Volunteers
- 79 people
- Sponsor
- Tamara Sorić
Schizophrenia
Intermittent Theta Burst Stimulation of the Precuneus
The purpose of the study is to compare the effectiveness of stimulation of the left precuneus by intermittent Theta Burst Stimulation to placebo stimulation on the severity of schizophrenia symptoms.
- Trial name
- Stim-TISiTBS (NCT06142422)
- Testing
- stimulation device
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Schizophrenia, Schizoaffective Disorder
Navigated αTMS in Treatment-resistant Schizophrenia
Since 1990s, stimulation of prefrontal cortex (PFC) has shown therapeutic effects on auditory hallucinations as well as negative symptoms of schizophrenia. However, previous studies have reported mixed or negative results.
- Trial name
- nTMS_NS (NCT01941251)
- Testing
- navigated Transcranial Magnetic Stimulation
- Where
- Finland
- Volunteers
- 50 people
- Sponsor
- Niuvanniemi Hospital
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine